Axsome Therapeutics (AXSM) Share-based Compensation (2015 - 2026)
Axsome Therapeutics recorded quarterly Share-based Compensation of $23.4 million in Q1 2026, up 3.11% quarter-over-quarter from $22.7 million in Q4 2025, and up 0.56% year-over-year from $23.3 million in Q1 2025.
Axsome Therapeutics' Share-based Compensation history runs 12 years deep, the most recent figure standing at $23.4 million for Q1 2026.
- In Q1 2026, Share-based Compensation rose 0.56% year-over-year to $23.4 million; the TTM figure through Mar 2026 stood at $93.9 million (up 6.28% YoY), while the FY2025 annual figure was $93.8 million, up 10.01% from the prior year.
- Share-based Compensation came in at $23.4 million for Q1 2026 at Axsome Therapeutics, up from $22.7 million in the prior quarter.
- In the past five years, Share-based Compensation ranged from a high of $37.7 million in Q4 2022 to a low of $7598.0 in Q1 2022.
- A 5-year average of $17.9 million and a median of $21.4 million in 2024 frame the typical range for Share-based Compensation.
- Across the five-year window, Share-based Compensation tumbled 99.84% in 2022 and soared 177871.08% in 2023, its largest moves.
- Axsome Therapeutics' Share-based Compensation stood at $37.7 million in 2022, then sank by 49.83% to $18.9 million in 2023, then increased by 16.24% to $22.0 million in 2024, then gained by 3.38% to $22.7 million in 2025, then increased by 3.11% to $23.4 million in 2026.
- According to Business Quant data, Share-based Compensation over the past three periods registered $23.4 million, $22.7 million, and $23.1 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Share-based Compensation (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 892,057.00 |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | 305,000.00 |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 166.40 Mn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 257.40 Mn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 70.15 Mn |
| 10 | Axsome Therapeutics | 11.82 Bn | 11.51 Bn | 176.48 Mn | 23.44 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 23.44 Mn |
| Mar 31, 2026 | 23.44 Mn |
| Dec 31, 2025 | 22.73 Mn |
| Dec 31, 2025 | 22.73 Mn |
| Sep 30, 2025 | 23.10 Mn |
| Sep 30, 2025 | 23.10 Mn |
| Jun 30, 2025 | 24.61 Mn |
| Jun 30, 2025 | 24.61 Mn |
| Mar 31, 2025 | 23.31 Mn |
| Mar 31, 2025 | 23.31 Mn |
| Dec 31, 2024 | 21.99 Mn |
| Dec 31, 2024 | 21.99 Mn |
| Sep 30, 2024 | 21.66 Mn |
| Sep 30, 2024 | 21.66 Mn |
| Jun 30, 2024 | 21.38 Mn |
| Jun 30, 2024 | 21.38 Mn |
| Mar 31, 2024 | 20.19 Mn |
| Mar 31, 2024 | 20.19 Mn |
| Dec 31, 2023 | 18.92 Mn |
| Dec 31, 2023 | 18.92 Mn |
| Sep 30, 2023 | 16.37 Mn |
| Sep 30, 2023 | 16.37 Mn |
| Jun 30, 2023 | 15.92 Mn |
| Jun 30, 2023 | 15.92 Mn |
| Mar 31, 2023 | 12.94 Mn |
| Mar 31, 2023 | 12.94 Mn |
| Dec 31, 2022 | 37.70 Mn |
| Dec 31, 2022 | 37.70 Mn |
| Sep 30, 2022 | 9,197.00 |
| Sep 30, 2022 | 9,197.00 |
| Jun 30, 2022 | 10,162.00 |
| Jun 30, 2022 | 10,162.00 |
| Mar 31, 2022 | 7,598.00 |
| Mar 31, 2022 | 7,598.00 |
| Dec 31, 2021 | 5.89 Mn |
| Dec 31, 2021 | 5.89 Mn |
| Sep 30, 2021 | 5.73 Mn |
| Sep 30, 2021 | 5.73 Mn |
| Jun 30, 2021 | 5.46 Mn |
| Jun 30, 2021 | 5.46 Mn |
| Mar 31, 2021 | 3.73 Mn |
| Mar 31, 2021 | 3.73 Mn |
| Dec 31, 2020 | 5.61 Mn |
| Dec 31, 2020 | 5.61 Mn |
| Sep 30, 2020 | 2.87 Mn |
| Sep 30, 2020 | 2.87 Mn |
| Jun 30, 2020 | 1.30 Mn |
| Jun 30, 2020 | 1.30 Mn |
| Mar 31, 2020 | 2.13 Mn |
| Mar 31, 2020 | 2.13 Mn |
| Dec 31, 2019 | 2.81 Mn |
| Dec 31, 2019 | 2.81 Mn |
| Sep 30, 2019 | 1.16 Mn |
| Sep 30, 2019 | 1.16 Mn |
| Jun 30, 2019 | 888,556.00 |
| Jun 30, 2019 | 888,556.00 |
| Mar 31, 2019 | 1.26 Mn |
| Mar 31, 2019 | 1.26 Mn |
| Dec 31, 2018 | 353,080.00 |
| Dec 31, 2018 | 353,080.00 |
| Sep 30, 2018 | 392,665.00 |
| Sep 30, 2018 | 392,665.00 |
| Jun 30, 2018 | 474,659.00 |
| Jun 30, 2018 | 474,659.00 |
| Mar 31, 2018 | 534,570.00 |
| Mar 31, 2018 | 534,570.00 |
| Dec 31, 2017 | 536,919.00 |
| Dec 31, 2017 | 536,919.00 |
| Sep 30, 2017 | 388,045.00 |
| Sep 30, 2017 | 388,045.00 |
| Jun 30, 2017 | 483,631.00 |
| Jun 30, 2017 | 483,631.00 |
| Mar 31, 2017 | 663,615.00 |
| Mar 31, 2017 | 663,615.00 |
| Dec 31, 2016 | 434,725.00 |
| Dec 31, 2016 | 434,725.00 |
| Sep 30, 2016 | 458,468.00 |
| Sep 30, 2016 | 458,468.00 |
| Jun 30, 2016 | 482,033.00 |
| Jun 30, 2016 | 482,033.00 |
| Mar 31, 2016 | 656,192.00 |
| Mar 31, 2016 | 656,192.00 |
| Dec 31, 2015 | 182,361.00 |
| Dec 31, 2015 | 182,361.00 |
| Sep 30, 2015 | 360,745.00 |
| Sep 30, 2015 | 360,745.00 |
| Jun 30, 2015 | 185,413.00 |
| Jun 30, 2015 | 185,413.00 |
| Mar 31, 2015 | 74,760.00 |
| Mar 31, 2015 | 74,760.00 |